Eli Lilly Opens Compassionate Use Pathway For Patients Needing Experimental Obesity Drug

Eli Lilly Opens Compassionate Use Pathway For Patients Needing Experimental Obesity Drug To qualify for retatrutide special use, patients must be at least 18, unable to take part in a clinical trial, have refractory obesity and two or more serious obesity-related complications, and have discussed all standard treatment options, Stat reported. Plus, two studies found no evidence linking MMR shots or circumcision to autism. https://kffhealthnews.org/morning-breakout/public-health-080426/